Abstract: Published online: December 30, 2020 Original Research Clinical outcomes after early ambulatory multidrug therapy for high-risk SARS-CoV-2 (COVID-19) infection Reviews in Cardiovascular Medicine Brian C. Procter1 , Casey Ross1 , Vanessa Pickard1 , Erica Smith1 , Cortney Hanson1 and Peter A. McCullough2,3,4, * 1 McKinney Family Medicine, McKinney, 75070, TX, USA 2 Baylor University Medical Center, Dallas, 75226, TX, USA 3 Baylor Heart and Vascular Institute, Dallas, 75226, TX, USA 4 Baylor Jack and Jane Hamilton Heart and Vascular Hospital, Dallas, 75226, TX, USA *Correspondence: peteramccullough@gmail.com (Peter A. McCullough) DOI:10.31083/j.rcm.2020.04.260 This is an open access article under the CC BY 4.0 license (https://creativecommons.org/licenses/by/4.0/). There is an emergency need for early ambulatory treatment of Coronavirus Disease 2019 (COVID-19) in acutely ill patients in an attempt to reduce disease progression and the risks of hospitalization and death. Such management should be applied in high-risk patients age > 50 years or with one or more medical problems including cardiovascular disease. We evaluated a total of 922 outpatients from March to September 2020. All patients underwent contemporary real-time polymerase chain reaction (PCR) assay tests from anterior nasal swab samples. Patients age 50.5 ± 13.7 years (range 12 to 89), 61.6% women, at moderate or high risk for COVID-19 received empiric management via telemedicine. At least two agents with antiviral activity against SARS-CoV-2 (zinc, hydroxychloroquine, ivermectin) and one antibiotic (azithromycin, doxycycline, ceftriaxone) were used along with inhaled budesonide and/or intramuscular dexamethasone consistent with the emergent science on early COVID-19 treatment. For patients with high severity of symptoms, urgent in-clinic administration of albuterol nebulizer, inhaled budesonide, and intravenous volume expansion with supplemental parenteral thiamine 500 mg, magnesium sulfate 4 grams, folic acid 1 gram, vitamin B12 1 mg. A total of 320/922 (34.7%) were treated resulting in 6/320 (1.9%) and 1/320 (0.3%) patients that were hospitalized and died, respectively. We conclude that early ambulatory (not hospitalized, treated at home), multidrug therapy is safe, feasible, and associated with low rates of hospitalization and death. Early treatment should be considered for high-risk patients as an emergency measure while we await randomized trials and guidelines for ambulatory management. Keywords SARS-CoV-2; COVID-19; multidrug; hospitalization; mortality; ambulatory; antiviral; zinc; hydroxychloroquine; ivermectin; doxycycline; azithromycin; vitamin; corticosteroid Rev. Cardiovasc. Med. 2020 vol. 21(4), 611–614 ©2020 Procter et al. Published by IMR Press. 1. Background The epidemic viral outbreak of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection Coronavirus Disease 2019 (COVID-19) is advancing across the United States unabated despite public policy measures focussed on contagion control (McCullough et al., 2020). The United States has a current 877 deaths per million inhabitants despite having technically advanced hospitals and to date sufficient capacity to handle the surges of patients requiring hospitalization (Worldometer, 2020). Conversely India, a country with broad implementation of early COVID-19 treatment has 102 deaths per million (Worldometer, 2020). The regulatory agencies as well as the National Institutes of..